ALFA Filings
Every announcement, straight from the exchange
Every Dr. Lal Pathlabs acquisition announcement on NSE and BSE, newest first, each with its own page.
Time
11 announcements with these filters
Dr. Lal PathLabs subscribed to WOS PUPL equity to fund PUPL's buyout of remaining 30% in CentraPath Labs for ₹30.3 Crore. CentraPath becomes a wholly owned subsidiary.
Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.
Dr. Lal PathLabs' subsidiary, DLPL Dubai, completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana. Sunshine Healthcare is now a step-down subsidiary.
Dr. Lal Path Labs Ltd. will acquire a 70% stake in SN Genelab Private Limited for Rs. 168 Crore to strengthen its genomics diagnostics portfolio.
Dr. Lal PathLabs approved the acquisition of a 70% stake in SN Genelab Private Limited for a total consideration of up to ₹199.5 Crore.
Dr. Lal Path Labs Ltd.'s subsidiary completed a 30% stake subscription in Neuome Technologies Private Limited for ₹3.50 Crore, making Neuome an associate company.
Dr. Lal PathLabs' subsidiary, Dr. Lal Ventures, has completed the acquisition of a 30% stake in Neuome Technologies Private Limited.
Dr. Lal Path Labs Ltd.'s subsidiary will acquire a 70% stake in Dr Lal PathLabs Indomed LLC to expand its diagnostics services in Uzbekistan.
Dr. Lal Path Labs Ltd. has completed the 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL) for ₹20 Crore. Following the transaction, SDCPL has become a wholly owned subsidiary of the company. This acquisition strengthens the company's diagnostic footprint.
Dr. Lal PathLabs Ltd. has successfully completed the 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL) on May 01, 2026. SDCPL is now a wholly-owned subsidiary of the company, following the terms of the Share Purchase Agreement signed on April 30, 2026.
Dr. Lal Path Labs Ltd. will acquire a 100% stake in Mumbai-based Shahbazkers Diagnostic Centre Private Limited for ₹20 Crore. The cash transaction is expected to conclude by May 31, 2026. This acquisition aims to strengthen the company’s diagnostic service presence in Mumbai, Maharashtra.